Considering the clinical efficacy and tolerable safety profile, an allosteric c-Abl inhibitor can potentially be used as a part of current combination regimens, which include bortezomib and lenalidomide, against MM. This evidence concerns the gene ABL1 and Miyoshi myopathy.